CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Financials Creative Medical Technology Holdings, Inc.
Equities
CELZ
US22529Y4089
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.45 USD | +2.53% |
|
+2.30% | -3.47% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 16.73 | 13.98 | 5.364 | 6.372 | 6.037 | - | - |
| Enterprise Value (EV) 1 | 16.73 | 13.98 | 5.364 | 6.372 | 6.037 | 6.037 | 6.037 |
| P/E ratio | -0.21 x | 0.39 x | -0.41 x | -1.23 x | -1.35 x | -1.72 x | 2 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 159 x | 60.5 x | 708 x | - | 10.7 x | 0.26 x |
| EV / Revenue | - | 159 x | 60.5 x | 708 x | - | 10.7 x | 0.26 x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 120 | 633 | 1,408 | 1,382 | 1,357 | - | - |
| Reference price 2 | 139.0 | 22.10 | 3.811 | 4.610 | 4.450 | 4.450 | 4.450 |
| Announcement Date | 3/17/21 | 3/30/22 | 3/31/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.0878 | 0.0886 | 0.009 | - | 0.563 | 23.41 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -3.126 | -10.24 | -5.62 | -4.941 | -4.738 | 8.61 |
| Operating Margin | - | -3,562.34% | -11,562.49% | -62,445.89% | - | -841.56% | 36.78% |
| Earnings before Tax (EBT) 1 | - | - | -10.14 | -5.287 | -4.68 | -4.398 | 9.12 |
| Net income 1 | -36.33 | 19.21 | -10.14 | -5.287 | -4.68 | -4.398 | 9.12 |
| Net margin | - | 21,893.75% | -11,449.26% | -58,739.67% | - | -781.17% | 38.96% |
| EPS 2 | -650.0 | 56.10 | -9.300 | -3.760 | -3.290 | -2.580 | 2.230 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/17/21 | 3/30/22 | 3/31/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.0678 | 0.015 | - | 0.055 | 0.0186 | - | - | 0.006 | 0.003 | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -1.473 | -1.155 | -1.791 | -1.02 | -6.278 | -1.113 | -1.192 | -1.543 | -1.772 | -1.123 | -1.26 | -1.273 | -1.285 |
| Operating Margin | -2,173.77% | -7,699.13% | - | -1,855.31% | -33,752.37% | - | - | -25,719.83% | -59,061.33% | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | -1.791 | -0.9823 | -6.216 | -1.052 | -1.102 | -1.454 | -1.679 | -1.042 | -1.19 | -1.213 | -1.235 |
| Net income 1 | -3.875 | -1.155 | -1.791 | -0.9823 | -6.216 | -1.052 | -1.102 | -1.454 | -1.679 | -1.042 | -1.19 | -1.213 | -1.235 |
| Net margin | -5,720.25% | -7,699.13% | - | -1,786.07% | -33,417.69% | - | - | -24,232.5% | -55,952.33% | - | - | - | - |
| EPS 2 | -41.60 | -1.800 | -2.000 | -0.7000 | -5.300 | -0.7000 | -0.7800 | -1.020 | -1.210 | -0.7300 | -0.8400 | -0.8500 | -0.8700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/22 | 5/13/22 | 8/12/22 | 11/10/22 | 3/31/23 | 5/12/23 | 8/11/23 | 11/14/23 | 3/22/24 | 5/10/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 3/17/21 | 3/30/22 | 3/31/23 | 3/22/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
4.45
USD
Average target price
30
USD
Spread / Average Target
+574.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.47% | 6.04M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.84B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- CELZ Stock
- Financials Creative Medical Technology Holdings, Inc.
